BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12479856)

  • 1. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
    Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
    Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
    Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
    Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
    Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
    J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
    Abi-Habib RJ; Liu S; Bugge TH; Leppla SH; Frankel AE
    Blood; 2004 Oct; 104(7):2143-8. PubMed ID: 15161668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
    Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
    Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
    Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
    J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
    Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
    Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
    Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
    Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
    Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
    Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
    Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
    Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
    Yalcintepe L; Frankel AE; Hogge DE
    Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
    Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
    Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Spisani S; Traniello S; Castoldi GL; Lanza F
    Eur J Histochem; 1997; 41 Suppl 2():109-10. PubMed ID: 9859806
    [No Abstract]   [Full Text] [Related]  

  • 16. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Rigolin GM; Balsamo R; Lanza F; Castoldi GL
    Boll Soc Ital Biol Sper; 1995; 71(5-6):141-7. PubMed ID: 8519488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
    Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
    Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
    Gutova M; Najbauer J; Gevorgyan A; Metz MZ; Weng Y; Shih CC; Aboody KS
    PLoS One; 2007 Feb; 2(2):e243. PubMed ID: 17327908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
    Rustamzadeh E; Vallera DA; Todhunter DA; Low WC; Panoskaltsis-Mortari A; Hall WA
    J Neurooncol; 2006 May; 77(3):257-66. PubMed ID: 16314943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.